Remove trial restrictions Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Merck
McKinsey
Johnson and Johnson
AstraZeneca

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR CINACALCET HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Cinacalcet Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00094484 ↗ Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis Completed Amgen Phase 3 2004-10-01 The purpose of this study is to evaluate the efficacy and safety of cinacalcet compared with placebo in patients with stage 3 and 4 Chronic Kidney Disease (CKD).
NCT00110890 ↗ A Research Study for Patients With End-Stage Renal Disease (ESRD) Completed Amgen Phase 4 2004-05-01 The purpose of this study is to evaluate the ability of a treatment strategy, that includes cinacalcet for the management of secondary hyperparathyroidism, to control parathyroid hormone (PTH) compared with the standard of care.
NCT00113945 ↗ Research Study Evaluating Cinacalcet for Patients With End Stage Renal Disease (ESRD) Completed Amgen Phase 2 2003-07-01 The purpose of this study is to observe the effects of a treatment strategy that incorporates cinacalcet HCl into the management of secondary hyperparathyroidism (HPT) in subjects with ESRD receiving hemodialysis, on bio-intact parathyroid hormone (biPTH), corrected serum calcium, serum phosphorus, and calcium phosphorus product.
NCT00113958 ↗ Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative (K/DOQI) Levels Completed Amgen Phase 2 1969-12-31 The purpose of this study is to observe the effects of a treatment strategy that incorporates cinacalcet HCl into the management of secondary hyperparathyroidism (HPT) to K/DOQI recommended targets in subjects with end stage renal disease (ESRD) receiving hemodialysis, on bio-intact parathyroid hormone, corrected serum calcium, serum phosphorus, and calcium phosphorus product.
NCT00117052 ↗ SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism Completed Amgen Phase 3 2004-09-01 The purpose of this study is to demonstrate that the efficacy of cinacalcet when co-administered with the first meal after dialysis is comparable (non-inferior) to the efficacy of cinacalcet when administered during the dialysis study visit.
NCT00195936 ↗ Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets Completed Children's Mercy Hospital Kansas City Phase 1 2005-06-01 This study will measure the effect of cinacalcet (Sensipar) on parathyroid hormone (PTH) secretion in children and adolescents with hypophosphatemic rickets (XLH). The investigators are seeking evidence that patients with XLH may benefit from treatment with cinacalcet by achieving better control of PTH secretion.
NCT00261950 ↗ Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease Completed Amgen Phase 2 2006-05-01 The purpose of this study is to evaluate the effects of cinacalcet on markers of bone turnover in patients with kidney disease who are receiving dialysis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cinacalcet Hydrochloride

Condition Name

Condition Name for Cinacalcet Hydrochloride
Intervention Trials
Secondary Hyperparathyroidism 23
Chronic Kidney Disease 13
Hyperparathyroidism, Secondary 6
End Stage Renal Disease 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cinacalcet Hydrochloride
Intervention Trials
Hyperparathyroidism 45
Hyperparathyroidism, Secondary 33
Neoplasm Metastasis 26
Kidney Diseases 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cinacalcet Hydrochloride

Trials by Country

Trials by Country for Cinacalcet Hydrochloride
Location Trials
United States 159
Spain 22
China 20
France 17
Canada 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cinacalcet Hydrochloride
Location Trials
New York 12
California 12
Missouri 10
Texas 9
Pennsylvania 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cinacalcet Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Cinacalcet Hydrochloride
Clinical Trial Phase Trials
Phase 4 19
Phase 3 14
Phase 2/Phase 3 3
[disabled in preview] 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cinacalcet Hydrochloride
Clinical Trial Phase Trials
Completed 44
Terminated 8
Unknown status 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cinacalcet Hydrochloride

Sponsor Name

Sponsor Name for Cinacalcet Hydrochloride
Sponsor Trials
Amgen 28
Kyowa Kirin Co., Ltd. 3
Kyowa Hakko Kirin Co., Ltd 2
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cinacalcet Hydrochloride
Sponsor Trials
Other 42
Industry 41
NIH 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Colorcon
Boehringer Ingelheim
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.